Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) – HC Wainwright issued their Q1 2025 earnings estimates for shares of Astria Therapeutics in a research note issued on Tuesday, March 11th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.50) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01.
Read Our Latest Analysis on Astria Therapeutics
Astria Therapeutics Stock Performance
ATXS opened at $6.45 on Friday. The firm has a 50 day moving average price of $7.19 and a 200 day moving average price of $9.57. The company has a market cap of $364.00 million, a PE ratio of -3.09 and a beta of 0.69. Astria Therapeutics has a 1 year low of $5.73 and a 1 year high of $16.90.
Institutional Trading of Astria Therapeutics
Several large investors have recently bought and sold shares of the company. FMR LLC grew its position in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. grew its position in Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares in the last quarter. Vestal Point Capital LP grew its position in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $25,680,000. Finally, Vanguard Group Inc. grew its position in Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after acquiring an additional 41,833 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
- Five stocks we like better than Astria Therapeutics
- Short Selling – The Pros and Cons
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Canadian Penny Stocks: Can They Make You Rich?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The Risks of Owning Bonds
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.